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ABSTRACT
There is often limited information available to establish clear dosage requirements in 
pregnant women, due to ethical concerns about clinical trials on this patient population. 
Some clinical evidence suggests that the physiological and biological changes which occur 
in the maternal body impact the pharmacokinetics (PKs) of antiretroviral drugs. This study 
aimed to develop a physiologically based pharmacokinetic (PBPK) model to characterise 
the effect of CYP2B6 metaboliser status on efavirenz (EFV) exposure through each 
trimester of pregnancy. Such models would be useful in predicting more appropriate 
dosing during pregnancy.
A PBPK model that accounted for the association between EFV PKs and CYP2B6  
polymorphism in a non-pregnant Caucasian population was developed using the Simcyp 
Population-Based Simulator (version 15; Simcyp, Sheffield, UK). Following verification of 
the model with clinical data, the model was applied to a virtual pregnant population in the 
third trimester. Clinical data, available in the public domain, was used to verify this model 
before it was used to predict EFV exposure in the first and second trimesters of 
pregnancy. The effect of CYP2B6 phenotypic status on EFV exposure, during the first 
(Ti), second (T2) and third trimester (T3) of pregnancy, were compared to determine 
whether trough plasma concentrations of EFV were within the acceptable therapeutic 
range.
The EFV PBPK model that accounted for CYP2B6 phenotypic status recovered the clinical 
data for extensive metabolisers (EM), intermediate metabolisers (IM) and poor 
metabolisers (PM), taking single and multiple doses of EFV, adequately. EFV PK changes 
associated with CYP2B6 metaboliser status was also adequately recovered for the third 
trimester (T3) of pregnancy, where median trough concentrations (Cmin) were predicted at 
0.99 mg I'1, 1.21 mg I' 1 and 2.54 mg I'1, for EM, IM and PM, respectively, which were within 
2-fold of the observed values. Predictions showed that during T3, 50 % EM had EFV 
trough concentrations (Cmin) below the accepted effective concentration of 1 . 0  mg I'1, 
suggesting that these patients may require an increased dose. During Ti and T2, 45 % of 
EM experienced sub-therapeutic EFV plasma concentrations. The percentage of IM who
had Cmin values below the therapeutic range were 27.14 % in Ti, 30.71 % in T2 and 41.43 
% in T3. Predictions of PM during T1 did not demonstrate any sub-therapeutic EFV plasma 
concentrations and only 3.33 % of PM experienced sub-therapeutic Cmin during T2 and T3.
The PBPK models effectively identified differences in plasma concentrations due to 
CYP2B6 metaboliser status, during the different trimesters of pregnancy. Such models 
can be used to facilitate the development of drug dosing regimens in pregnant populations. 
Furthermore the capability of the predictive model can be extended to evaluate untested 
drug dosages, drug-drug interactions and metabolic interactions associated with 
polymorphisms.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
■ The physiologically altered maternal body has a large impact on the disposition and 
pharmacokinetics of antiretroviral drugs.
■ Efavirenz is an important component of first-line antiretroviral regimens and is 
predominantly metabolised by the isoform CYP2B6.
• CYP2B6 metaboliser status has been shown to affect the magnitude of efavirenz 
autoinduction and efavirenz exposure significantly.
WHAT THIS STUDY ADDS
■ The pregnancy PBPK (p-PBPK) model in this study was used to characterise the 
association between CYP2B6 polymorphisms and efavirenz pharmacokinetics 
during the first, second and third trimester of pregnancy.
■ The model was used to identify the probability of pregnant women having sub- 
therapeutic plasma concentrations based on their CYP2B6 metaboliser status.
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Schematic representation of the workflow of PBPK model development. 
Simulated mean (green line) and observed [9] EFV plasma concentrations, 
of extensive (A), intermediate (B) and poor (C) CYP2B6 metabolisers, after 
single-dosing (600 mg). The grey lines represent the 95th and 5th percentiles 
of the predicted EFV concentrations.
Simulated mean (green line) and observed [4] (coloured circles) EFV plasma 
concentrations, of extensive (A), intermediate (B) and poor (C) CYP2B6  
metabolisers, at steady-state. The grey lines represent the 95th and 5th 
percentiles of the predicted EFV concentrations.
Simulated mean (green line) and observed [4] (coloured circles) EFV plasma 
concentrations, of extensive (A), intermediate (B) and poor (C) CYP2B6  
metabolisers, at steady-state, during third trimester (T3: 37 weeks) of 
pregnancy. The grey lines represent the 95th and 5th percentiles of the 
predicted EFV concentrations.
Simulated mean Cmin concentrations for extensive CYP2B6 metabolisers, 
intermediate CYP2B6 metabolisers and poor CYP2B6 metabolisers, during 
T1 (A), T2 (B) and T3 (C) of pregnancy.
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CYP2B6 input parameters.
Clinical and predicted PK parameters for EFV after single-dose oral administration 
(600 mg), in extensive, intermediate and poor CYP2B6 metabolisers.
Median (IQR) clinical and predicted EFV PK parameters, at steady- 
state (600 mg), in extensive, intermediate and poor CYP2B6  
metabolisers.
Median (IQR) clinical and predicted EFV PK parameters, at steady-state 
(600 mg), during pregnancy (T3), in extensive, intermediate and poor 
CYP2B6 metabolisers.
Effect of CYP2B6 polymorphism on mean EFV PK during pregnancy based 
on the predicted EFV PK for Ti, T2 and T3.
Percentage change in EFV PK during pregnancy in extensive, intermediate 
and poor CYP2B6 metabolisers, based on simulated mean data reflected in 
Table 5.
Acquired immune deficiency syndrome (AIDS) is the most frequent cause of death in 
pregnant women in many Southern African countries [1] and antiretroviral treatment 
(ART) of maternal human immunodeficiency virus (HIV) infection is widely used. 
Changes in the body, as a result of pregnancy can influence the absorption, 
distribution, metabolism and elimination of drugs [2], The physiologically altered 
maternal body has a large impact on the disposition and PKs of antiretroviral (ARV) 
drugs [3]. Significant inter-individual variability in the PKs of ARVs in pregnant 
women, due to single nucleotide polymorphisms (SNPs) in drug disposition genes, 
has been observed clinically [4], Due to the clinical and ethical concerns associated 
with the inclusion of pregnant women in clinical trials, there is often limited or no 
information available to establish clear dosage requirements for pregnant women [5], 
Suboptimal drug exposure can result in HIV ribonucleic acid (RNA) rebound, the 
presence of a resistant virus strain, or an increased risk of HIV-1 transmission to the 
infant [6 ]. Increased drug exposure can produce unwarranted maternal adverse 
effects and/or foetal toxicity [6 ].
First-line ART regimens include the use of a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTI) [7]. 
Efavirenz (EFV) is a common component of first-line ART regimens [4], as it is 
considered to have extensive efficacy and safety documentation, in contrast to other 
NNRTIs [8 ]. EFV is predominantly metabolised by the isoform CYP2B6 [4] and 
CYP2B6 metaboliser status has been shown to affect EFV exposure significantly [4, 
9, 10, 11, 12, 13, 14, 15, 16, 17 and 18],
Several studies have investigated EFV exposure, associated with CYP2B6  
polymorphism in subjects who were not pregnant. Xu e t al. [9] and Haas et al. [10] 
studied the effect of CYP2B6 polymorphism, following administration of a single dose 
of EFV in healthy populations. Both studies demonstrated an increase in EFV area 
under the concentration-time curve (AUC) and a decrease in apparent oral clearance 
(CL/F) in individuals carrying the CYP2B6 516T—>T phenotype (poor CYP2B6
l
metabolisers (PM)) when compared to individuals carrying the CYP2B6 516G—>G 
phenotype (extensive CYP2B6 metabolisers (EM)) [9, 10].
A study of Zimbabwean patients showed that the CYP2B6 516G—>T (intermediate 
CYP2B6 metaboliser (IM)) and PM were associated with a decrease in EFV CL/F by 
22% and 57 % respectively [11], PM occur with high frequency in African 
populations and dose reductions have been recommended as very high EFV plasma 
concentrations may result in increased adverse effects, including serious central 
nervous system adverse reactions, and subsequent treatment discontinuation [1 2 , 
13]. Siccardi e t al. [12] investigated the effects of EFV dose reduction (from 600 mg 
to 400 mg and 200 mg) on PKs in a cohort of 500 virtual subjects with different 
CYP2B6 phenotypes. This study suggested that dose reductions would be 
favourable for both IM and PM [12], Cabrera e t al. [14] described a decrease in EFV 
CL/F of 50 % and 75 %, in a Caucasian population, in IM and PM, respectively [14].
Kwara et al. [15] considered the effect of CYP2B6 genetic variation on the steady- 
state PKs of EFV in a Ghanaian, HIV/tuberculosis (TB) co-infected population. The 
study demonstrated that EFV AUC was significantly higher, and CL/F was 
significantly lower, in PM when compared to EM [15], In a study of 273 HIV-infected 
patients, receiving 600 mg EFV daily, Dickinson e t al. [16] reported low EFV median 
trough concentrations (Cmin) in EM and described the associated risk of potential 
virological failure [16].
Studies on possible changes in EFV exposure, during pregnancy, are sparse. 
Cressey et al. [17] studied EFV exposure in a HIV-infected, pregnant population, 
during the third trimester (T3) [17], The study demonstrated that EFV CL/F was 
increased during pregnancy; however, CYP2B6 polymorphisms were not explored in 
the study [17],
A study was conducted by Olagunju et al. [4] in 25 pregnant (first two trimesters (Ti 
and T2): n = 7; third trimester (T3): n = 18) and 19 different postpartum, HIV-positive
women. Results obtained by Olagunju e t al. [4] demonstrated no significant 
differences in EFV PKs between the first two trimesters and T3 [4]. As such, all 25 
pregnant women were included in the analysis and the results showed comparisons 
between pooled EFV PKs in pregnancy vs. post-partum [4], CL/F in pregnant 
patients was 42.6 % higher than in postpartum patients [4], The increase in CL/F 
was attributed to enhanced CYP2B6 activity associated with the increased 170- 
estradiaol plasma concentration, during pregnancy [4], Pregnancy-induced changes 
in EFV PKs, were observed in EM and PM [4], whereby CL/F increased by 100 % 
and 45.6 % respectively [4], EFV PKs were not affected by pregnancy-induced 
changes in IM [4],
Dooley et al. [18] studied a prospective cohort of 97 pregnant, HIV-infected women, 
during T3. The findings of the study suggested that the main determinant of EFV 
hepatic intrinsic clearance (CLint) was CYP2B6 phenotype [18]. Women with 
extensive CYP2B6 metaboliser status demonstrated rapid CL/F of EFV and were at 
increased risk of attaining EFV concentrations which fell below the therapeutic 
threshold, adopted in 2001, of 1.0 mg I' 1 [18, 19].
The few studies in pregnant women suggest that EFV exposure during pregnancy 
may change considerably and is likely to be influenced by the CYP2B6 metaboliser 
status of the individual.
Physiologically-based pharmacokinetic (PBPK) models can facilitate the 
development of drug dosing regimens for populations which are considered to be 
high-risk during clinical studies, such as pregnant populations [20]. PBPK models 
use a bottom-up approach whereby in vivo data are predicted through the in vitro-in  
vivo extrapolation (IVIVE) of known data [20], PBPK modelling has the advantage of 
incorporating both physiological and biochemical parameters that are important for 
pharmacokinetic processes and drug-specific parameters (e g. physico-chemical and 
drug disposition characteristics), into a quantitative predictive model, that can be 
used to predict the pharmacokinetics of drugs and develop suitable drug dosing 
regimens [21], Anatomical, physiological and metabolic changes, occurring in the 
maternal body, can be incorporated into pregnant-PBPK (p-PBPK) models [22].
Thus, the p-PBPK model can be used to predict the impact of physiological changes
during pregnancy, such as enzyme induction or inhibition [22] on the PKs of drugs. 
As such, p-PBPK modelling can potentially be used to predict PK changes and 
corresponding dose adjustments in pregnancy to ensure adequate drug efficacy and 
avoid undesirable toxicity [23]. A PBPK pregnancy model is available in the Simcyp 
simulator. As discussed by De Sousa Mendes e t a l [22], “the model accounts for 
maternal changes such as increasing body weight, fat mass, cardiac output, plasma 
volume, glomerular filtration rate (GFR), renal plasma flow and decreasing 
haematocrit, albumin and a1-acid glycoprotein” and has been described by Gaohua 
et al. and Ke et al. [21, 24], Changes in the activity of CYP3A4, CYP2D6 and 
CYP1A2 are also incorporated in the current model [24].
This study aimed to develop a model to describe the impact of CYP2B6 metaboliser 
status on the PKs of a standard 600mg dose of EFV in pregnant women. Such a 
model will be useful to determine whether dosage adjustments are required during 
pregnancy, based on CYP2B6  metaboliser status. In future studies, the p-PBPK 
model will be useful to predict interactions with EFV that may require dosage 
adjustments. This is of particular relevance for EFV since it is usually administered in 
combination with other drugs.
METHODS 
Computer Software
All simulations in this study were performed using the Simcyp Population-Based 
Simulator (version 15; Simcyp, Sheffield, UK) [8 ],
Non-pregnant Caucasian Population Model
The Caucasian population in the Simcyp simulator was used to represent the non­
pregnant individuals. However, the model does not account for differences in 
metabolism due to CYP2B6 phenotypic differences.CYP2B6 protein expression in 
liver tissue was revised to account for phenotypic differences, based on data from 
Lang and co-workers [25], as shown in Table 1.
Table 1
CYP2B6 input parameters.
CYP2B6 liver
CV%112,251CYP2B6 phenotype
abundance112251
EM 24 pmol/mg of protein 68 %
IM 17 pmol/mg of protein 80 %
PM 8 pmol/mg of protein 97%
EM = extensive CYP2B6 metabolisers; IM = intermediate CYP2B6 metabolisers; PM = poor CYP2B6 
metabolisers, CV = coefficient of variation.
Pregnancy population model
The Pregnancy model available in the Simcyp simulator was used for simulations in 
this study. The general structure of the p-PBPK model, the associated assumptions 
made and verification were described in detail previously by Gaohua e t al. [24], The 
model accounts for systemic gestational age-dependent parameter changes in the 
physiology and biochemistry that occurs during the progression of pregnancy [26]. 
Since the model did not account for CYP2B6 metaboliser status or pregnancy- 
induced hepatic CYP2B6 induction, the CYP2B6 abundance was increased 1.1-fold, 
1.4-fold and 1.9-fold, during Ti, T2 and T3, respectively, as described by Ke et al. [21, 
27],
Verification and application of an EFV PBPK model to predict the impact of 
CYP2B6 metaboliser status on PKs.
The EFV PBPK model described by Ke et al. [28] was used in this study. The model 
accounts for metabolism, predominantly by CYP2B6, contribution by CYP3A4, 
CYP2A6  and CYP1A2 , and CYP2B6 and CYP3A4 autoinduction [28], The EFV 
model was verified in Caucasian healthy volunteers by Ke e t al. [28] but no 
differentiation, in the PKs of the drug, due to CYP2B6 metaboliser status, was 
accounted for. In this study, the EFV model was evaluated and verified for the 
prediction of PK differences associated with CYP2B6 metaboliser status in non­
pregnant Caucasian subjects and thereafter verified in a pregnant population.
The general strategy used to evaluate the effect of CYP2B6 phenotypic status on 
EFV PKs during pregnancy is represented in the workflow diagram in Figure 1.
Observed PK profile 
Observed PK Parameters
Observed PK profile 
Observed PK Parameters
Observed PK profile 
Observed PK Parameters
EFV PBPK model 
(Single Dose: 600 mg EFV) 
(Steady State: 600 mg EFV)
*
*
Model Validation
Non-pregnant Caucasian Model
Model Validation
Pregnant Caucasian Model (T3)
♦
Model Validation
Simulation of EFV PK parameters during 
Tt and T2
Refinement:
CYP2B6 
protein 
expression in 
liver tissue 
(Table 1)
Simulation:
EFV PK 
differences 
associated 
with CYP2B6 
metaboliser 
status
Simulation:
EFV PK 
differences 
associated 
with CYP2B6 
metaboliser 
status
Figure 1
Schematic representation of the workflow of PBPK model development.
To verify and evaluate the PBPK models, predicted concentration-time profiles for 
EFV in the three CYP2B6 phenotypes were compared to those observed in clinical 
studies. Visual predictive tests were performed on the concentration time profiles. In 
addition, the predicted median exposure parameters (AUC, Cmax and CL/F) were 
compared with the observed values from the clinical studies. The 2-fold prediction 
error, used for model validation in this study, is commonly used in the justification of 
predictions in IVIVE studies [29]. Abduljalil et al. [29] described that, for drugs with 
high variability, a 2.5-fold metric system may be applied [29]. The 2-fold system 
would be appropriate for drugs with medium variability and a tighter boundary of 1.5- 
fold is suggested for drugs with low variable PK parameters [29]. The 2-fold criteria 
boundaries have been applied in this study.
Where tabulated concentration-time data was not available in the literature, data 
were extracted from the observed figures available, using the GetData graph 
digitiser, version 2.2. PBPK models were found to be acceptable when inspection of 
the median concentration-time profiles showed that majority of the clinically observed 
data points were within the 95% and 5% percentiles and the PK parameter 
estimations were predicted within 2 -fold of the observed data.
The trial design of the simulations was based on the clinical studies that were used 
for comparison and verification. To verify the ability of the model to recover the 
phenotypic differences in EFV PKs in non-pregnant individuals, observed single-dose 
EFV PK data was obtained from Xu e t al. [9] and Haas et al. [10]and PK data of EFV 
exposure at steady-state was obtained from Olagunju et a/.(HIV-infected patients; 
pregnant: n = 25; post-partum: n = 19), 100 % female) [4], Kwara et a l.(26 HIV/TB co­
infected patients, 31 % female) [15] and Dickinson et a l.(273 HIV-infected patients,
32 % female) [16].
The verified PBPK model was extrapolated to the pregnant population and was used 
to predict the PK profiles of EFV, for each phenotype. The trial designs were based 
upon studies conducted by Dooley e t al. [18] and Olagunju et al. [4].The study by 
Dooley and co-workers [18] evaluated concentration-time profiles for 600 mg EFV 
given once daily in women in the third trimester of pregnancy in South African 
subjects. Olagunju and co-workers [4] studied concentration-time profiles for 600 mg 
EFV given once daily in women in pregnancy (first two trimesters (Ti and T2): n = 7; 
third trimester (T3): n = 18), in Nigerian subjects. The median AUC, CL/F, CmaXand 
CminOf EFV (600 mg) were predicted, for each phenotype, for T3, and verified using 
the clinical data.
The PBPK model was then used to predict the impact of CYP2B6 metaboliser status 
on the PKs of EFV in T, and T2, in the absence of clinical data. 10 trials of 10 
individuals were predicted for each phenotype to account for variability. For 
comparison with T3, median EFV PK parameters and concentration-time profiles 
were predicted for Tt and T2 so as to characterise the association between CYP2B6
polymorphisms and EFV PKs throughout pregnancy. Predicted Cmin concentrations 
during each trimester of pregnancy, for each CYP2B6 phenotype, were then 
compared to determine whether dose adjustments may be required.
RESULTS
Model evaluation for the non-pregnant population 
Single-dose EFV PKs
The observed and predicted values for the PK parameters (CL/F, AUCo -», and Cmax), 
following a single dose of EFV (600 mg), are summarised in Table 2 and are all 
within a 2-fold range of observed values. 77.8 % of the results observed for PK 
parameters, in the single-dose study of EFV exposure, were within a 1.25-fold range 
of the reported data.
Table 2
Clinical and predicted PK parameters for EFV after single-dose oral administration (600 mg), in extensive, intermediate and poor CYP2BL 
metabolisers.
EXTENSIVE CYP2B6 METABOLISERS
CL/F (I h'1) AUC (mg h I'1) Cmax(mg I*1)
Xu etal. [9] (n = 8)
(mean values)
8.5 (± 3.4) 79.8 (± 28.4) 2.3 (± 0.7)
Simulated (n = 8) 11.16 63.73 2.59
Pred icted/Observed 1.31 0.80 1.13
Haas et al. [10] (n = 10)
(median values)
7.57 (4.89-12.53) 68.00 (47.00-102.00) 1.64(1.47-1.91)
Simulated (n = 10) 8.02 74.78 2.65
P red icted/Obse rved 1.06 1.10 1.62
INTERMEDIATE CYP2B6 METABOLISERS
CL/F (I h 1) AUC (mg h I 1) Cmax(mg I*1)
Xu etal. [9] (n = 9)
(mean values)
8.3 (± 2.8) 81.6 (± 33.7) 1.7 (± 0.5)
Simulated (n = 9) 9.35 77.05 2.74
Predicted/Observed 1.13 0.94 1.61
Haas etal. [10] (n = 17)
(median values)
7.14 (5.47 -  8.38) 77.00 (63.00 -  99.00) 1.88 (1 .38-2 .40)
Simulated (n = 17) 6.80 88.28 2.65
Predicted/Observed 0.95 1.15 1.41
POOR CYP2B6 METABOLISERS
CL/F (I h 1) AUC (mg h I*1) Cmax(mg I 1)
Xu et a/. [9] (n = 3)
(mean values)
5.9 (± 0.5) 101.7 (±7.9) 2.4 (± 0.2)
Simulated (n = 3) 6.85 93.96 2.85
Predicted/Observed 1.16 0.92 1.19
Haas etal. [10] (n = 7)
(median values)
4.09 (3.90 -  4.55) 123.00 (102.00-128.00) 2.34(1.78-2.52)
Simulated (n = 7) 4.20 142.93 2.89
Predicted/Observed 1.03 1.16 1.24
PK = pharmacokinetic; EFV = efavirenz; CL/F = oral clearance; AUC = area under the plasma concentration time curve; Cmax = maximum plasma concentration; SD 
standard deviation; IQR = interquartile range.
As shown in Figure 2, the overall PK profile showed satisfactory agreement with the 
clinical observations [9], although there appeared to be a trend towards over­
prediction in the IM and PM groups. The high variability between the subjects could 
account for this. Predicted PK parameters demonstrated higher CL/F and lower AUC 
in EM when compared to IM and PM in accordance with observed PK data obtained 
from Xu et al. [9] and Haas et al. [10].
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Figure 2
Simulated mean (green line) and observed [9] EFV plasma concentrations, of 
extensive (A), intermediate (B) and poor (C) CYP2B6 metabolisers, after single­
dosing (600 mg). The grey lines represent the 95th and 5th percentiles of the 
predicted EFV concentrations.
Multiple-dose EFV PKs
Predictions of multiple-dose EFV PK parameters were compared with clinical data 
obtained from Olagunju e t al. [4], Kwara et al. [15] and Dickinson e t al. [16], Results 
provided in Table 3 demonstrate that 75 % of the results predicted for PK parameters 
(CL/F, AUC, Cmax and Cmin), were within a 1.25-fold range of the reported data and 
96 % of the results were within a 2-fold range (Table 3).
Table 3
Median (IQR) clinical and predicted EFV PK parameters, at steady-state (600 mg), in extensive, intermediate and poor 
CYP2B6 metabolisers.
EXTENSIVE CYP2B6 METABOLIZERS
CL/F (I h'1) AUCo.24(mg h I 1) Cmax(mg I 1) Cmm(mg I'1)
Olagunju et al. [4] (n = 6) 11.60 (9.37-18.40) 52.40 (32.60 -  64.00) 3.19(2 .70-3 .80) 1.54 (0 .87-2 .31)
Simulation (n = 6) 13.21 45.41 3.31 1.02 (0 .56-1 .55)
Predicted/Observed 1.14 0.87 1.04 0.66
Kwara et al. [11] (n = 7) 24.60(19.44-51.84) 24.40(11.80-30.90) 1.60 (1 .20-2.00) 0.60 (0 .20-0 .90)
Simulation (n =  7) 14.76 40.67 2.94 0.89 (0 .57-1 .27)
Predicted/Observed 0.6 1.67 1.84 1.48
Dickinson ef al. [16] (n = 107) 12.40 (5.11 -69 .70) 49.20 (8.61 - 117.00) 2.80(1 .53-5 .79) 1.28 (0.0025-3.94)
Simulation (n =  107) 15.42 38.92 2.92 0.82 (0 .54-1 .26)
Predicted/Observed 1.24 0.8 1.04 0.64
INTERMEDIATE CYP2B6 METABOLIZERS
CL/F (I h’1) AUC0.24 (mg h I'1) Cmax(mg I'1) Cmm(mg r 1)
Olagunju eta l. [4] (n =  7) 11.90 (4.71 -20.67) 50.70 (29.00-128.00) 4.85 (2.05 -  6.78) 1.52 (0 .76-4.86)
Simulation (n =  7) 9.90 60.58 4.06 1.55 (0 .87-2.32)
Predicted/Observed 0.83 1.19 0.84 1.02
Kwara e ta l.  [11] (n = 12) 28.86 (18.42-38.82) 24.80 (16.60-40.30) 1.80 (1 .20-2.10) 0.50 (0 .30-1.20)
Simulation (n =  12) 11.93 50.30 3.40 1.19(0.70-1.79)
Predicted/Observed 0.41 2.03 1.89 2.38
Dickinson e ta l. [16] (/? =  127) 8.93 (2.98 -  65.40) 67.60 (12.40-202.00) 3.71 (1 .69-9.03) 1.94 (0 .079-7.55)
Simulation (n =  127) 11.78 50.94 3.42 1.23 (0 .80-1.82)
Predicted/Observed 1.32 0.75 0.92 0.63
POOR CYP2B6 METABOLIZERS t'
CL/F (I h'1) AUC0.24(m g h l1) Cma„(mg I'1) Cmin (mg I'1)
Olagunju et al. [4] (n =  6) 4.69 (3.39 -  5.35) 129.00 (112.00-177.00) 6.94 (6.37 -  9.76) 5.13(3 .83-6 .74)
Simulation (n =  6) 6.43 93.35 5.47 2.75(1 .58-3 .76)
Predicted/Observed 1.37 0.72 0.79 0.54
Kwara et al. [11] (#7 =  7) 8.04 (4.62-10.14) 74.70 (59.10-133.70) 4.30 (2.90 -  7.00) 2.80 (2 .10-4.70)
Simulation (n =  7) 7.24 82.93 4.74 2 .44(1 .54-3 .22)
Predicted/Observed 0.90 1.11 1.10 0.87
Dickinson et al. [16] (n =  39) 3.55 (1.69-58.20) 171.00 (19.20-359.00) 7.80(1 .75-15.60) 6.24 (0.24-14.10)
Simulation (n = 39) 7.32 81.96 4.90 2.17 (1 .72-3 .46)
Predicted/Observed 2.06 0.48 0.63 0.35
IQR = interquartile range; EFV = efavirenz; PK = pharmacokinetic; CL7F = oral clearance; AUC = area under the plasma concentration time curve; Cmax 
maximum plasma concentration; Cmin = EFV trough concentration.
Figure 3 shows predicted vs. observed [4] concentration-time courses for EFV (600 
mg) exposure at steady-state. The EFV plasma concentration values, reported by 
Olagunju et al. [4], were within the 5th and 95th percentile of the simulation, 
suggesting good recovery of the clinical data.
(A)
Simulated mean (green line) and observed [4] (coloured circles) EFV plasma 
concentrations, of extensive (A), intermediate (B) and poor (C) CYP2B6  
metabolisers, at steady-state. The grey lines represent the 95th and 5th percentiles of 
the predicted EFV concentrations.
While the majority of the predicted parameters were within the 2-fold range, slight 
over-predictions were observed in the predicted median AUC (50.30 mg h I'1) and 
Cmin (1.19 mg I'1), for IM, when compared with the observed median values of AUC 
(24.80 mg h I'1) and Cmin (0.50 mg I'1) obtained from Kwara et al. [15]. The predicted 
median CL/F of 7.32 I h '\ for poor CYP2B6 metabolisers, was also slightly over­
predicted when compared to the observed CL/F of 3.55 I h' 1 described by Dickinson 
e ta l. [16].
Based on the trial design described by Olagunju e ta l. [4], the predicted EFV PK 
parameters demonstrated 105.44 % higher CL/F, 51.36 % lower AUC, 39.49 % lower 
Cmax and 62.91 % lower Cmin in EM when compared to PM.
EFV PKs in pregnancy (T3)
The overall PK profiles, for EM, IM and PM, during T3 showed good agreement with 
the clinical observations, for acceptable predictability, within the 5th and 
95mpercentiles [4] (Figure 4). 83.33 % of the predicted PK parameters (CL/F, AUC, 
Cmax and C mjn), during T3 were within a 1.25-fold range of the reported data, obtained 
from Olagunju et al. [4] and 100 % of the predictions were within 2-fold of the clinical 
data [4],
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Simulated mean (green line) and observed [4] (coloured circles) EFV plasma 
concentrations, of extensive (A), intermediate (B) and poor (C) CYP2B6  
metabolisers, at steady-state, during third trimester (T3: 37 weeks) of pregnancy. 
The grey lines represent the 95th and 5th percentiles of the predicted EFV 
concentrations.
As shown in table 4, the predicted median CL/F and AUC for each CYP2B6  
phenotype, during T3were well predicted and within 1.25-fold and 1.5-fold, 
respectively, of the observed data [4], The predicted Cmax values, for EM, IM and 
PM, during T3were very well predicted [4], Cmjn was predicted at 0.99 mg I'1, 1.21 mg 
I' 1 and 2.54 mg I'1, for EM, IM and PM, respectively, which was within 2-fold of the 
observed Cmin reported by Olagunju e ta l. [4],
Table 4
Median (IQR) clinical and predicted EFV PK parameters, at steady-state (600 mg), during pregnancy (T3), in extensive, 
intermediate and poor CYP2B6 metabolisers.
EXTENSIVE CYP2B6 METABOLIZERS
CL/F (I h 1) AUC (mg h I'1) Cmax(mg I'1) Cmin(mg F1)
Olagunju etal. [4] (n = 8) 23.2(18.4-27.7) 25.9 (21.7-32.6) 2.64(1.26-3.49) 0.59 (0.43 -  0.92)
Simulation (n = 8) 15.86 37.85 2.56 0.99 (0 .60-1.53)
Predicted/Observed 0.68 1.46 0.97 1.68
Dooley et al. [18] (n = 18) - - - 0.79 (0 .67-1 .02)
Simulation (n = 18) 18.55 32.35 2.33 0.72 (0 .47-1 .21)
Predicted/Observed - - - 0.91
INTERMEDIATE CYP2B6 METABOLIZERS
CL/F (I h’1) AUC (mg h I'1) Cmax(mg I'1) Cmm(rng I'1)
Olagunju et al. [4] (n = 14) 13.7 (2.96-23.3) 43.90 (25.7 -  203.00) 3.66 (2.49 -14 .4 ) 1 .12(0 .57-5 .19)
Simulation (n = 14) 13.66 43.93 2.89 1.21 (0.81 -2 .03)
Predicted/Observed 1.00 1.00 0.79 1.08
Dooley et al. [18] (n = 43) - - - 1.38 (1 .09-1.81)
Simulation (n = 43) 14.50 41.38 2.75 1.06( 0 .65-1 .72)
Predicted/Observed - - - 0.77
POOR CYP2B6 METABOLI2ERS
CL/F (1 h'1) AUC (mg h I'1) Cmax(mg I'1) C m in  (mQ I )
Olagunju et al. [4] (n = 3) 6.83 (5.22-8.15) 87.9 (73.7-115.0) 5.77 (5.32 -  5.95) 2.89 (2 .66-4 .03)
Simulation (n = 3) 7.72 77.68 4.28 2.54 (1.81 -3 .88 )
Predicted/Observed 1.13 0.88 0.74 0.88
Dooley et al. [18] (n = 10) - - 4.09 (3 .52-6 .54)
Simulation (n = 10) 8.94 67.12 3.95 2.07 (1.41 -3 .45 )
Predicted/Observed - - - 0.51
IQR = interquartile range; EFV = efavirenz; PK = pharmacokinetic; T3= third trimester: 37 weeks; CL/F = oral clearance; AUC = area under the plasma concentration 
time curve; 0 ^  = maximum plasma concentration; Cmin = EFV trough concentration.
As reflected in Table 4, observed data for Cmin were extracted from Dooley e t al. [18]. 
No additional PK parameters (such as CL/F, AUC, and Cmax), stratified by phenotype, 
during T3, were reported by Dooley et al. [18], The predicted Cmin values accurately 
recovered the observed values in EM, IM and PM in T3 [18], Sub-therapeutic EFV 
concentrations were observed in EM, during T3 [18, 19]. Predicted median Cmjn in 
EM, during T3, were below the therapeutic threshold of 1.0 mg I'1.
Recovery of the clinical data [4, 18] by the pregnancy model suggested that it was 
suitable for application to predict EFV PK changes during pregnancy based on 
CYP2B6 metaboliser status. Predicted mean Cmin concentrations, during the three 
trimesters of pregnancy, are shown in Figure 5 and the impact of CYP2B6  
phenotypes on EFV PK parameters during T1 , T2 and T3 of pregnancy is shown in 
Table 5.
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Figure 5
Simulated mean Efavirenz (EFV) trough concentrations (Cmin) for extensive CYP2B6  
metabolisers (EM), intermediate CYP2B6 metabolisers (IM) and poor CYP2B6  
metabolisers (PM), during Ti (A), T2 (B) and T3 (C) of pregnancy.
Table 5
Effect of CYP2B6 polymorphism on mean EFV PK during pregnancy based on the predicted EFV PK for T1 , T2 and T 3 .
THIRD T R IM E S T E R : 37 W E E K S
PK parameter CL/F (I h'1) AUC (mg h I’1) Cmax(rng r 1) Cmin(mg I'1)
Simulation EM (n = 100) 18.38 32.64 2.32 0.99 (0 .6 0 -1 .5 3 )
Simulation IM (n=  100) 13.92 43.12 2.83 1.21 (0.81 -2 .0 3 )
Simulation PM (n = 100) 9.31 64 46 3.77 2.54(1.81 -3 .8 8 )
PM vs. EM: % change 49.35 % - 97.49 % - 62.50 % -1 5 6 .5 7 %
IM vs. EM: % change 24.27 % -32.11 % -2 1 . 98 % - 2 2 . 2 2  %
S E C O N D  T R IM E S T E R : 22 W E E K S
PK parameter CL/F (I h'1) AUC (mg h I'1) Cmax (mg r 1) Cmin(mg I 1)
Simulation EM (/? = 100) 16.68 35.97 2.55 1 .1 3 (0 .6 7 -1 .7 3 )
Simulation IM (n = 100) 1 2 . 6 6 47.38 3.11 1.37 (0 .9 1 -2 .3 2 )
Simulation PM (n = 100) 8.57 70.05 4.09 2.90 (2 .0 4 -4 .2 7 )
PM vs. EM: % change 48.62 % - 94.75 % -6 0 .3 9  % - 156.64 %
IM vs. EM: % change 24 .10% -3 1 .7 2 % -2 1 .9 6 % -2 1 .2 4 %
F IR S T  T R IM E S T E R : 10  W E E K S
PK parameter CL/F (I h'1) AUC (mg h I*1) Cmax (mg I'1) Cmin(mg l‘1)
Simulation EM (n = 100) 14.78 40.60 2.89 1.19 (0.71 -1 .8 5 )
Simulation IM (n = 100) 1 1 . 2 2 53.48 3.52 1.46 (0 .9 6 -2 .4 7 )
Simulation PM (n = 100) 7.61 78.81 4.62 3.13 (2 .1 8 -4 .6 0 )
PM vs. EM: % change 48.51 % -94.11 % - 59.86 % - 163.03%
IM vs. EM: % change 24.09 % -3 1 .7 2 % -2 1 .8 0 % - 22.69 %
Data are geometric mean. EFV = efavirenz; PK = pharmacokinetic; CL/F = oral clearance; AUC = area under the plasma concentration time curve; Cmax = maximum 
plasma concentration; Cmin = EFV trough concentration; EM = extensive CYP2B6 metabolisers; IM = intermediate CYP2B6 metabolisers; PM = poor CYP2B6 
metabolisers.
PM vs. EM percentage change was calculated as follows:
EM - P M
IM vs. EM percentage change was calculated as follows:
E M - I M  
EM
*100
The PBPK model was used to predict the extent to which EFV PKs were affected, by 
CYP2B6 phenotype during each trimester of pregnancy (Table 5). During T3> EFV 
CL/F was 49.35 % higher in EM, compared to PM (Table 5). EFV AUC, during T3) 
was 97.49 % lower, in EM, compared to PM (Table 5). EFV CL/F in EM, during T3, 
increased by 19.59 %, when compared to Ti and increased by 9.05 % when 
compared to T2 (Table 6). EFV AUC, in EM, during T3 decreased by 7.45 % in T2 
and by 12.65 % in T3 (Table 6). Predictions showed that during T3, 50 % EM had 
EFV trough concentrations (Cmin) below the accepted effective concentration of 1.0 
mg I'1. During Ti and T2,45 % of EM experienced sub-therapeutic EFV plasma 
concentrations. The percentage of IM who had Cmjn values below the therapeutic 
range were 27.14 % in Ti, 30.71 % in T2 and 41.43 % in T3. Predictions of PM during 
Ti did not demonstrate any sub-therapeutic EFV plasma concentrations and only 
3.33 % of PM experienced sub-therapeutic Cmin during T2 and T3.
Table 6
Percentage change in EFV PK during pregnancy in extensive, intermediate and poor CYP2B6 metabolisers, based on simulated 
mean data reflected in Table 5.
E X T E N S IV E  C Y P 2B 6  M E T A B O LIZE R S
CUF (I h'1) AUC (mg h l‘1) Cmax(mg r 1 ) C m i n  (mg I'1)
Ti vs. T3: % change 19.59 - 24.39 - 24.57 - 20.20
T2 vs. T3: % change 9.25 - 10.20 - 9.91 - 14.14
IN TER M ED IA TE C YP 2B6  M ETA B O LIZER S
CUF (I h 1) AUC (mg h I'1) Cmax (mg I'1) C m i n  (nig 1 )
T-i vs. T3: % change 19.40 - 24.03 - 24.38 -  20.66
T2 vs. T3: % change 9.05 - 9.88 - 9.90 -  13.22
PO O R  C Y P 2B 6  M ETA B O LIZER S
CUF (1 h 1) AUC (mg h I'1) Cmaxlmg I'1) C m i n  (nig I )
T, vs. T3: % change 18.26 -  22.26 - 22.55 - 23.23
T2 vs. T3: % change 7.95 - 8.67 - 8.49 -  14.17
oral clearance; AUC = area under the plasma concentration time curve; Cmax = 
concentration.
Ti vs. T3: percentage change was calculated as follows:
7 3 -7 1  
— — — x 100 
T 3
T2 vs. T3 percentage change was calculated as follows:
T 3 - T 2  
— ——  x 100 
T 3
= maximum plasma concentration; Cmin = EFV trough
DISCUSSION
The PBPK model developed in this study was able to successfully predict EFV 
exposure, associated with CYP2B6 EM, IM and PM phenotypes, following 
administration of a single dose of EFV (600 mg), as well as multiple doses, in non­
pregnant, Caucasian subjects, as well as pregnant subjects in the third trimester of 
pregnancy.
Predicted single-dose (Table 2) and multiple dose (Table 3) EFV PKs demonstrated 
higher CL/F and lower AUC, Cmin and Cmax in EM when compared to PM, as 
observed clinically [4, 9, 10, 15, 16]. As with the observations made in two studies 
[4, 16] higher CL/F was predicted in IM compared with PM. However, no significant 
difference was observed in EFV exposure or CL/F between IM and PM, in a study 
conducted by Kwara et al. [15]. It is uncertain whether co-medication can explain this 
difference since the patients in the study by Kwara and co-workers [15] had both HIV 
and TB. In addition, the patients in the Kwara e t al. [15] study were of African origin.
Differences in the predicted PKs in the third trimester of pregnancy in EM, IM and PM 
were similar to those observed in the clinical studies [16, 17, 19]. Increased CL/F of 
EFV in EM resulted in Cmin values, at steady-state, that were very close to or below 
the therapeutic EFV Cmin of 1.0 mg I"1 [19]. The findings are in accordance with the 
results reported by Dickinson et al. [16] who suggest that decreased Cmin values in 
EM exposed patients, carrying the CYP2B6 516G—>G phenotype (EM), to the risk of 
virological failure [16].
Olagunju e t al. [4] reported a significant increase in CL/F in pregnant patients 
compared with postpartum patients [4], The study conducted by Cressey e t al. [17] 
also demonstrated increased EFV CL/F and reduced exposure during pregnancy, 
particularly during T3 [17]. CYP2B6 induction during pregnancy is the likely 
explanation for the observed phenotype-dependent differences in the magnitude of 
pregnancy-induced changes [4]. Weight increases, synonymous with the 
progression of pregnancy have also been reported to increase the CL/F of EFV [18].
The verified PBPK model was extrapolated to a pregnant population to simulate the 
PK profiles of EFV, during Ti and T2 for each phenotype. The predicted EFV PK 
demonstrated a progressive increase in CL/F and decrease in exposure (AUC, Cmjn 
and Cmax) from Ti to T3 for all phenotypes, with the most significant increase in CL/F 
occurring in EM in T3. The highest EFV CL/F (18.38 I h'1) and lowest EFV AUC 
(32.64 mg h I'1) were predicted in EM during T3. Studies conducted by Olagunju et 
at. [4] and Dooley e t at. [18] also demonstrated significantly lower AUC and Cmjn in 
EM during T3 and sub-therapeutic EFV Cmjn, (below 1.0 mg I'1) in pregnant women 
with the CYP2B6 516G->G phenotype (EM), during T3 [4, 18].
Cmin did not fall below the therapeutic range, in PM, during T  ^and a very small 
percentage of PM demonstrated sub-therapeutic Cmin, during T2 and T3. The 
percentage of IM, with Cmjn below the therapeutic threshold, increased through the 
progression of pregnancy (Ti -  T3), but not to the same extent as EM. As such, the 
standard daily dose of 600mg appears to be adequate for the IM and PM 
phenotypes. EM experienced sub-therapeutic concentrations of EFV throughout 
pregnancy; particularly during T3 (50 % of patients), and thus it can be seen that 
dosage adjustments may be required in EM during T3.
Pharmacogenetic testing may be a useful tool for optimising EFV dosage strategies 
during pregnancy. Dose adjustments must be carefully considered in pregnant 
populations and the altered drug PKs in the maternal body need to be understood in 
order to achieve the desired therapeutic effectiveness of drug treatment in pregnant 
women [3], Considering the clinical and ethical concerns associated with clinical 
trials in a pregnant population, PBPK models are useful for predicting expected PK 
changes and the corresponding need for dosage adjustments. The results of this 
study lend support to the recommendation that increased EFV dosage regimens 
could be considered for pregnant women with EM status.
A limitation of this study was that the simulations were performed in a Caucasian 
pregnant population. Extrapolation of the model to other ethnic groups may be 
useful. A further limitation to the study was identified in that the study focused on the
CYP2B6 polymorphism in position 516G->T and CYP2B6 mutations at positions 
785A-»G, 983C-*T and 1459C-+T were not explored. Recommendations for 
improvement on this study design would include the development of an African 
pregnancy population that accounts for differences in demographics, physiology, 
biochemistry and metabolism between the ethnic groups [30], Further clinical studies 
focusing on the verification of the predictions made in this study, especially for T-i and 
T2, would be useful.
Furthermore the capability of the predictive model can be extended to evaluate 
untested drug dosages, drug-drug interactions and metabolic interactions associated 
with enzyme polymorphisms. The applicability of PBPK models to therapeutics can 
be further enhanced by combination with pharmacodynamics models [31],
In conclusion, this study demonstrates that PBPK modelling can be used to 
successfully predict the PK profiles of drugs in a pregnant population, based on CYP 
metaboliser phenotype. Such predictions are useful in identifying patient sub-groups 
who may require dosage adjustments.
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Waiver of Ethical Clearance (W-CJ-160829-1) 
Approval for Change of Title
Effect of CYP2B6 polymorphism on mean EFV PK during pregnancy based on the predicted mean EFV PK forT1t T2 
and T3.
THIRD T R IM E S T E R : 37 W E E K S  !
PK parameter C L /F  (I h'1) A U C  (mg h T1) C max(mg I’1) C mln(mg I'1)
Simulation EM (n = 100) 18.38 32.64 2.32 0.99 (0 .6 0 -1 .5 3 )
Simulation IM (n = 100) 13.92 43.12 2.83 1.21 (0.81 -2 .0 3 )
Simulation PM (n = 100) 9.31 64.46 3.77 2.54(1.81 -3 .8 8 )
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Simulation EM (n = 100) 16.68 35.97 2.55 1.13 (0.67 —1.73)
Simulation IM (n = 100) 12.66 47.38 3.11 1.37 (0 .9 1 -2 .3 2 )
Simulation PM (n = 100) 8.57 70.05 4.09 2.90 (2 .0 4 -4 .2 7 )
d m  wo p m  0/ , u , nnfl 1 6 .6 8 -8 .5 7  3 5 .9 7 -  70.05 2 .5 5 -4 .0 9  1.13 - 2 .9 0
PM vs. EM % change -----77- 7^-----x 100 = 48.62 ----- -------------*  100 = -94.75 --------------- *  100 = -60 .39  -----— -----x 100 = -156 .6416.68 35.97 2.55 1.13
IM vs. EM: %  change
16.68 -  12.66 y in n  -  in 35.97 -  47.38 2 .5 5 -3 .1 1 v 1 nn  91  o /: 1 .1 3 -1 .3 7 v 1 nn 9 1 9 a
16.68 * 100 2 4 ’ 10 35.97 *  100 -  31 72 2.55 X l 0 ° “  2 1 '9 6
. „  _ X iUU — Z 1.Z4
1.13
FIR S T  T R IM E S T E R : 10  W E E K S
PK  parameter C L /F  (1 h '1) A U C  (mg h I’1) Cmax (mg I'1) c mln (mg i'1)
Simulation EM (n = 100) 14.78 40.60 2.89 1 .1 9 (0 .7 1 -1 .8 5 )
Simulation IM (n = 100) 11.22 53.48 3.52 1.46 (0 .9 6 -2 .4 7 )
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EFV = efavirenz; PK = pharmacokinetic; CL/F = oral clearance; AUC = area under the plasma concentration time curve; Cmax = maximum plasma concentration; Cmin
EFV trough concentration; EM = extensive CYP2B6 metabolisers; IM = intermediate CYP2B6 metabolisers; PM = poor CYP2B6 metabolisers.
PM vs. EM percentage change was calculated as follows:
E M - P M
EAf X 100
IM vs. EM percentage change was calculated as follows:
EM - I M
'em
x 100
Percentage change in EFV PK during pregnancy in extensive, intermediate and poor CYP2B6 metabolisers, based on simulated mean data 
reflected in Table 5.
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INTERMEDIATE CYP2B6  METABOLIZERS
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POOR CYP2B6 METABOLIZERS
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EFV = efavirenz; PK = pharmacokinetic; T  ^ = first trimester: 10 weeks; T2 = second trimester: 22 weeks; T3 = third trimester: 37 weeks; CL/F -  
oral clearance; AUC = area under the plasma concentration time curve; Cmax = maximum plasma concentration; Cmin = EFV trough
concentration.
T i vs. T3: percentage change was calculated as follows:
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T2 v s . T3 percentage change was calculated as follows:
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